Bexsero®

BIOLOGICAL4 trials

Sponsors

GlaxoSmithKline, Canadian Immunization Research Network, Assistance Publique - Hôpitaux de Paris, Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)

Conditions

Infections, MeningococcalMeningococcal DiseaseMeningococcal Serogroup BNeisseria Meningitidis Serogroup BSplenectomy

Phase 1

A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104

Not yet recruitingNCT07395739

Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)Neisseria Meningitidis Serogroup B

Start: 2026-02-24End: 2027-05-31Target: 30Updated: 2026-02-09

Phase 3

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

CompletedNCT02173704

GlaxoSmithKlineInfections, Meningococcal, Meningococcal Disease

Start: 2014-09-11End: 2016-06-17Updated: 2020-08-25

Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

RecruitingNCT04166656

Assistance Publique - Hôpitaux de ParisSplenectomy

Start: 2022-09-15End: 2028-10-31Target: 84Updated: 2025-11-20

Phase 4

Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults

CompletedNCT02583412

Canadian Immunization Research NetworkMeningococcal Serogroup B

Start: 2015-09-30End: 2017-06-30Updated: 2019-01-31

Related Papers

Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.

2019-07-0310 citations

Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study

Human Vaccines & Immunotherapeutics2018-01-1614 citations